Repositioning the Bolus Tracking ROI to the Superior Vena Cava in CTPA Facilitates Contrast Volume Reduction
Key facts
- Who runs it
- Hospital Queen Elizabeth, Malaysia
- Where
- Malaysia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 72 people enrolled
- Started
- 1 Feb 2023
- Ended
- 16 Dec 2024
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Optimized CTPA Protocol
- Record updated
- 15 January 2026
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- All patients scheduled for a Computed Tomography Pulmonary Angiography (CTPA) examination
- Provision of written informed consent by the subject, guardian, or medical specialist
- Patients with an upper extremity intravenous (IV) line using a 16-20 gauge cannula
- Patients with a stable heart rate between 60 and 120 beats per minute (bpm)
Who cannot take part
- Patients with a lower extremity IV line, as this bypasses the Superior Vena Cava (SVC) and results in bolus tracking technique failure
- Patients with a heart rate lower than 60 bpm or higher than 120 bpm
- Patients with severe cardiac impairment or congenital heart disease
- Patients with impaired renal function, including acute kidney injury or chronic kidney disease (CKD) with an eGFR less than 30 mL/min/1.73m²
- Pregnancy, breastfeeding, or use of non-reliable methods of contraception
- Patients with a cannula size of 22g or smaller, as it cannot accommodate the high flow rate (4 mL/s) required by the power injector
- Patients with a Body Mass Index (BMI) exceeding 35 kg/m², as severe obesity causes beam hardening effects that degrade image quality
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized controlled trial evaluates a protocol optimization for Computed Tomography Pulmonary Angiography (CTPA). The study investigates the impact of repositioning the bolus-tracking region-of-interest (ROI) from the standard pulmonary trunk (PT) to the superior vena cava (SVC). The goal is to compensate for the CT scanner's inherent transit delay time (TDT) to better align the scan with the peak arterial phase. By optimizing this timing, the study assesses whether contrast media volume can be safely reduced by 40% (from 50 ml to 30 ml) while maintaining diagnostic image quality and preventing venous contamination.
The 4 groups in the trial
- Group A: PT-ROI, 50 ml (Control)Existing treatment, for comparison
Standard CTPA protocol using the bolus tracking technique with the monitoring region of interest (ROI) placed at the pulmonary trunk (PT) and 50 ml of contrast media.
Treatment: Optimized CTPA Protocol
- Group B: PT-ROI, 30 mlTreatment being tested
Modified CTPA protocol using the bolus tracking technique with the monitoring ROI at the pulmonary trunk (PT) and a reduced contrast volume of 30 ml.
Treatment: Optimized CTPA Protocol
- Group C: SVC-ROI, 50 mlTreatment being tested
Modified CTPA protocol using the bolus tracking technique with the monitoring ROI repositioned upstream to the superior vena cava (SVC) and 50 ml of contrast media.
Treatment: Optimized CTPA Protocol
- Group D: SVC-ROI, 30 mlTreatment being tested
Modified CTPA protocol using the bolus tracking technique with the monitoring ROI repositioned upstream to the superior vena cava (SVC) and a reduced contrast volume of 30 ml.
Treatment: Optimized CTPA Protocol
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Optimising Bolus Tracking Technique by Repositioning the Region of Interest (ROI) at the Superior Vena Cava and Reducing Contrast Media Volume in Computed Tomography Pulmonary Angiography (CTPA)
- Record updated
- 15 January 2026